ECU
REGN icon

Eisler Capital (US)’s Regeneron Pharmaceuticals REGN Stock Holding History

Eisler Capital (US)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,082
Closed -$2M – 669
2024
Q1 		$2M Buy
+2,082
New +$1.98M 0.05% 282
2023
Q2 		– Sell
-4,455
Closed -$3.66M – 352
2023
Q1 		$3.66M Buy
+4,455
New +$3.36M 0.29% 84

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Eisler Capital (US)'s REGN Position: Q2 2024 in Review

Eisler Capital (US) sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 2,082 shares — an estimated $2M sold.

Eisler Capital (US) first reported a position in REGN in Q1 2023 and held it in 2 quarters. The position peaked at $3.66M in Q1 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Eisler Capital (US) reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 2,082 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $2M.
  • Eisler Capital (US) first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Eisler Capital (US)'s Regeneron Pharmaceuticals position peaked at $3.66M in Q1 2023.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Eisler Capital (US)'s 13F filing for Q2 2024, filed 13 Aug 2024.